Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Generate Biomedicines, Inc. reports Schedule 13G disclosures from Flagship-related entities showing aggregated control positions in Common Stock. The filing lists shares outstanding of 128,192,484 as of March 31, 2026. The excerpt shows Flagship Pioneering, LLC holds 62,673,117 shares (48.9%) and related Flagship vehicles hold multiple additional positions, including Flagship VentureLabs VI, LLC: 25,016,458 shares (19.5%), Flagship Pioneering Fund VII, L.P.: 16,827,224 shares (13.1%), and Flagship Pioneering Fund VI, L.P.: 12,723,940 shares (9.9%). The filing identifies the Reporting Persons, their addresses, citizenships, and the voting/dispositive power reported for each entity.
Insights
Flagship entities disclose concentrated ownership in Generate Biomedicines.
The filing documents large shared voting and dispositive power among Flagship vehicles, with 62,673,117 shares held by Flagship Pioneering, representing 48.9% of the class as of March 31, 2026. Such concentration can affect voting outcomes for corporate actions.
Dependencies include the relationships between the Reporting Persons and their GP/manager structures; subsequent disclosures could clarify whether holdings are aggregated for control purposes. Future filings may report changes in these positions.
Disclosure clarifies ownership baselines for investors and the company's register.
The cover rows list voting and dispositive power by entity, citing the issuer's 128,192,484 shares outstanding as of March 31, 2026. The filing identifies persons who may be deemed to beneficially own shares through GP/manager relationships.
Cash‑flow treatment or transfer intent is not stated in the excerpt; subsequent Schedule 13D/F or Form 4 filings would show transactional activity if holders trade or change control intent.
Key Figures
Shares outstanding:128,192,484 sharesFlagship Pioneering holdings:62,673,117 sharesFlagship VentureLabs VI holdings:25,016,458 shares+3 more
6 metrics
Shares outstanding128,192,484 sharesas of March 31, 2026
Flagship Pioneering holdings62,673,117 sharesreported beneficially owned, 48.9% of class
Flagship VentureLabs VI holdings25,016,458 sharesreported beneficially owned, 19.5% of class
Flagship Fund VII holdings16,827,224 sharesreported beneficially owned, 13.1% of class
Flagship Fund VI holdings12,723,940 sharesreported beneficially owned, 9.9% of class
Pioneering Medicines 02, LLC holdings1,562,500 sharesreported beneficially owned, 1.2% of class
Key Terms
beneficially own, shared dispositive power, Schedule 13G, general partner
4 terms
beneficially ownregulatory
"The information required by this item with respect to each Reporting Person is set forth"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared dispositive powerregulatory
"Shared Dispositive Power 62,673,117.00"
Schedule 13Gregulatory
"Item 1. Name of issuer: Generate Biomedicines, Inc."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
general partnerfinancial
"Flagship Fund VI GP is the general partner of Flagship Fund VI"
A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Flagship Pioneering report in Generate Biomedicines (GENB)?
Flagship Pioneering reports beneficial ownership of 62,673,117 shares, equal to 48.9% of the class. The filing ties percentages to 128,192,484 shares outstanding as of March 31, 2026, and lists related Flagship entities and voting/dispositive power.
How many shares of Generate Biomedicines are outstanding as reported?
The filing cites 128,192,484 shares of Common Stock outstanding as of March 31, 2026. That figure is used to calculate the ownership percentages reported for each Flagship Reporting Person.
Which Flagship entities hold material positions in GENB per the filing?
Material Flagship positions include Flagship Pioneering (62,673,117; 48.9%), Flagship VentureLabs VI (25,016,458; 19.5%), Flagship Fund VII (16,827,224; 13.1%). The cover rows show voting and dispositive power for each entity.
Does the Schedule 13G show who controls the Flagship holdings?
Yes; the report identifies GP and manager relationships and states that Flagship Pioneering and Dr. Noubar B. Afeyan may be deemed to beneficially own the shares. It lists each Reporting Person and their organizational roles.
Are trading intentions or plans disclosed in this Schedule 13G?
No trading intentions or transaction plans are included in the excerpt. The filing lists beneficial ownership, voting/dispositive power, and organizational relationships without stating any sale or acquisition intent.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Generate Biomedicines, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
370920100
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship Pioneering Fund VI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
12,723,940.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
12,723,940.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,723,940.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship Pioneering Fund VI General Partner LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
12,723,940.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
12,723,940.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,723,940.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Pioneering Medicines 02, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,562,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,562,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,562,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship Pioneering Fund VII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
16,827,224.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
16,827,224.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
16,827,224.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.1 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship Pioneering Fund VII General Partner LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
16,827,224.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
16,827,224.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
16,827,224.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.1 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Nutritional Health LTP Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
987,491.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
987,491.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
987,491.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.8 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Nutritional Health LTP Fund General Partner LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
987,491.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
987,491.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
987,491.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.8 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship Pioneering Special Opportunities Fund II, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,777,752.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,777,752.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,777,752.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.2 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship Pioneering Special Opportunities Fund II General Partner LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,777,752.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,777,752.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,777,752.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
FPN II, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
ONTARIO, CANADA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,340,252.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,340,252.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,340,252.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.4 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
FPN General Partner LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,340,252.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,340,252.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,340,252.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.4 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship VentureLabs VI, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
25,016,458.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
25,016,458.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
25,016,458.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
19.5 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship VentureLabs VI Manager LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
25,016,458.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
25,016,458.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
25,016,458.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
19.5 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Flagship Pioneering, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
62,673,117.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
62,673,117.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
62,673,117.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
48.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
370920100
1
Names of Reporting Persons
Afeyan Noubar
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
28,798.00
6
Shared Voting Power
62,673,117.00
7
Sole Dispositive Power
28,798.00
8
Shared Dispositive Power
62,673,117.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
62,701,915.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
48.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Generate Biomedicines, Inc.
(b)
Address of issuer's principal executive offices:
101 South Street, Suite 900, Somerville, MA 02143
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
(i) Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI").
(ii) Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP").
(iii) Pioneering Medicines 02, LLC ("PM02").
(iv) Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII").
(v) Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP").
(vi) Nutritional Health LTP Fund, L.P. ("Nutritional LTP").
(vii) Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP").
(viii) Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II").
(ix) Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP").
(x) FPN II, L.P. ("FPN II Fund").
(xi) FPN General Partner LLC ("FPN GP").
(xii) Flagship VentureLabs VI, LLC ("VentureLabs VI" and together with Flagship Fund VI, PM02, Flagship Fund VII, Nutritional LTP, Flagship Opportunities Fund II and FPN II Fund, the "Flagship Funds").
(xiii) Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager" and together with Flagship Fund VI GP, Flagship Fund VII GP, Nutritional LTP GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship GPs").
(xiv) Flagship Pioneering, LLC ("Flagship Pioneering").
(xv) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is:
c/o Flagship Pioneering
55 Cambridge Parkway, Suite 800E
Cambridge, Massachusetts 02142
(c)
Citizenship:
(i) Flagship Fund VI: Delaware
(ii) Flagship Fund VI GP: Delaware
(iii) PM02: Delaware
(iv) Flagship Fund VII: Delaware
(v) Flagship Fund VII GP: Delaware
(vi) Nutritional LTP: Delaware
(vii) Nutritional LTP GP: Delaware
(viii) Flagship Opportunities Fund II: Delaware
(ix) Flagship Opportunities Fund II GP: Delaware
(x) FPN II Fund: Ontario, Canada
(xi) FPN GP: Delaware
(xii) VentureLabs VI: Delaware
(xiii) VentureLabs VI Manager: Delaware
(xiv) Flagship Pioneering: Delaware
(xv) Dr. Afeyan: United States
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP Number(s):
370920100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 128,192,484 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on May 7, 2026. Flagship Fund VI GP is the general partner of Flagship Fund VI and may be deemed to beneficially own the shares held directly by Flagship Fund VI. Flagship Fund VII is the majority equity holder of PM02 and may be deemed to beneficially own the shares held directly by PM02. Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02. Flagship Fund VII GP is the general partner of Flagship Fund VII and may be deemed to beneficially own the shares held directly by each of PM02 and Flagship Fund VII. Nutritional LTP GP is the general partner of Nutritional LTP and may be deemed to beneficially own the shares held directly Nutritional LTP. Flagship Opportunities Fund II GP is the general partner of Flagship Opportunities Fund II and may be deemed to beneficially own the shares held directly by Flagship Opportunities Fund II. FPN GP is the general partner of FPN II Fund and may be deemed to beneficially own the shares held directly by FPN II Fund. VentureLabs VI Manager is the manager of VentureLabs VI and may be deemed to beneficially own the shares held directly by VentureLabs VI. Flagship Pioneering, as the manager of each of the Flagship GPs, and Dr. Afeyan, as the ultimate control person of Flagship Pioneering, may each be deemed to beneficially own the shares held directly by the Flagship Funds.
(b)
Percent of class:
See Item 4(a).
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Row 5 of cover page for each Reporting Person.
(ii) Shared power to vote or to direct the vote:
See Row 6 of cover page for each Reporting Person.
(iii) Sole power to dispose or to direct the disposition of:
See Row 7 of cover page for each Reporting Person.
(iv) Shared power to dispose or to direct the disposition of:
See Row 8 of cover page for each Reporting Person.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Flagship Pioneering Fund VI, L.P.
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager of Manager of General Partner
Date:
05/15/2026
Flagship Pioneering Fund VI General Partner LLC
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager of Manager
Date:
05/15/2026
Pioneering Medicines 02, LLC
Signature:
/s/ Charles R. Carelli, Jr.
Name/Title:
Charles R. Carelli, Jr., Manager
Date:
05/15/2026
Flagship Pioneering Fund VII, L.P.
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager of General Partner
Date:
05/15/2026
Flagship Pioneering Fund VII General Partner LLC
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager
Date:
05/15/2026
Nutritional Health LTP Fund, L.P.
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager of Manager of General Partner
Date:
05/15/2026
Nutritional Health LTP Fund General Partner LLC
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager of Manager
Date:
05/15/2026
Flagship Pioneering Special Opportunities Fund II, L.P.
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan Ph.D., Sole Member and Manager of Manager of Manager of General Partner
Date:
05/15/2026
Flagship Pioneering Special Opportunities Fund II General Partner LLC
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan Ph.D., Sole Member and Manager of Manager of Manager
Date:
05/15/2026
FPN II, L.P.
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager of Manager of General Partner
Date:
05/15/2026
FPN General Partner LLC
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager of Manager
Date:
05/15/2026
Flagship VentureLabs VI, LLC
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager of Manager of Manager
Date:
05/15/2026
Flagship VentureLabs VI Manager LLC
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager of Manager
Date:
05/15/2026
Flagship Pioneering, LLC
Signature:
/s/ Noubar B. Afeyan, Ph.D.
Name/Title:
Noubar B. Afeyan, Ph.D., Sole Member and Manager of Manager
